CPI-1189: Phase IIa

Interim results from Centaur's U.S. Phase IIa trial in 64 HIV infected patients with AIDS dementia showed that CPI-1189 was well tolerated, with >90 percent of CPI-1189-treated patients completing the 10-week blinded portion of the study compared to 76 percent of the placebo group. After 10 weeks, however, neither group showed progression of cognitive or motor disability, which Centaur said made it impossible to assess the ability of CPI-1189 to arrest cognitive decline. ...